Hematopoietic stem-cell transplants in chronic lymphocytic leukemia.
| . | Autologous . | Allogeneic . | NMA-Allogeneic . |
|---|---|---|---|
| (1)Indicates that chemosensitivity of the disease is a necessary condition for the success of the procedure | |||
| Abbreviations: NMA-Allogeneic, Non-myeloablative allogeneic transplants; GVL, graft-versus-leukemia; TRM, transplant related mortality; RR, relapse rate; OS, overall survival | |||
| Age limit (yrs) | 70 | 50-60 | 60-70 |
| Need for response (1) | yes | no | no? |
| Antitumor effect | cytotoxic agents | cytotoxic + GVL | GVL |
| TRM | 10% | 25-50% | <10-20% (at 1 yr) |
| RR (4 yrs) | 50% | 10-25% | 10-20% (at 1 yr) |
| OS (4 yrs) | 40-70% | 40-60% | ? (60-80% at 1 yr) |
| Plateau | no | yes | ? |
| . | Autologous . | Allogeneic . | NMA-Allogeneic . |
|---|---|---|---|
| (1)Indicates that chemosensitivity of the disease is a necessary condition for the success of the procedure | |||
| Abbreviations: NMA-Allogeneic, Non-myeloablative allogeneic transplants; GVL, graft-versus-leukemia; TRM, transplant related mortality; RR, relapse rate; OS, overall survival | |||
| Age limit (yrs) | 70 | 50-60 | 60-70 |
| Need for response (1) | yes | no | no? |
| Antitumor effect | cytotoxic agents | cytotoxic + GVL | GVL |
| TRM | 10% | 25-50% | <10-20% (at 1 yr) |
| RR (4 yrs) | 50% | 10-25% | 10-20% (at 1 yr) |
| OS (4 yrs) | 40-70% | 40-60% | ? (60-80% at 1 yr) |
| Plateau | no | yes | ? |